The gene therapy developer focused on cardiovascular and central nervous system diseases will merge with Chardan Healthcare Acquisition 2 Corp to list on NYSE.

Renovacor, a US-based gene therapy developer spun out of Temple University, agreed to a reverse merger with special purpose acquisition company Chardan Healthcare Acquisition 2 Corp on Tuesday. The deal includes $30m of private investment in public equity (Pipe) at $10 a share and, together with approximately $86m held in Chardan’s trust account from its…

The rest of this content is only accessible to University Venturing: News, Data and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.